Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 553-563

  Dennison, Jennifer B ^a   Jones, David R ^a   Renbarger, Jamie L ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; ITRACONAZOLE; VINCRISTINE;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; GENOTYPE; HUMAN; HUMAN TISSUE; KINETICS; LINEAR REGRESSION ANALYSIS; LIVER CLEARANCE; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE CHARACTERIZATION; WESTERN BLOTTING;

CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; KINETICS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PROTEIN BINDING; VINCRISTINE;

EID: 34247371529     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118471     Document Type: Article

References (41)

1. 3H]-vincristine in man. Clin Pharmacol Ther 22:430-435.
2. Bohme A, Ganser A, and Hoelzer D (1995) Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71:311-312.
3. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, and Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327.
4. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, and Kerb R (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231-236.
5. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, Del Favero A, Rossetti R, Tonato M, Rambotti P, et al. (1989) Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64:1805-1811.
6. Frost BM, Lonnerholm G, Koopmans P, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Uges DR, and de Graaf SS (2003) Vincristine in childhood leukemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 92:551-557.
7. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
8. He P, Court MH, Greenblatt DJ, and Von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-387.
9. He P, Court MH, Greenblatt DJ, and Von Moltke LL (2006) Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 34:1198-1207.
10. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy S, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, and Mizugaki M (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417-421.
11. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
12. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
13. Hustert E, Haberl M, Burk O, Wolbold R, He Y, Klein K, Nuessler A, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
14. Isoherranen N, Kunze KL, Allen KE, Nelson WL, and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131.
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins P, Daly A, Wrighton S, Hall S, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
16. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W, Heerema NA, Wimmer RS, Trigg ME, and Sather HN (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-833.
17. Le CP, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, et al. (2004) Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 76:139-153.
18. Li XQ, Weidolf L, Simonsson R, and Andersson TB (2005) Enantiomer/enantiomer interactions between the S-and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther 315:777-787.
19. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 amd contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, and Holt DW (2002) Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74:1486-1489.
22. Mayer LD and St-Onge G (1995) Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 232:149-157.
23. McCune J and Lindley C (1997) Appropriateness of maximum dose guidelines for vincristine. Am J Health Syst Pharm 54:1755-1758.
24. Nelson R (1982) The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol 10:115-127.
25. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
26. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromesP450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938-944.
27. Pollock B, DeBaun M, Camitta B, Shuster J, Ravindranath Y, Pullen D, Land V, Mahoney DJ, Lauer S, and Murphy S (2000) Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 18:813-823.
28. Rahmani R and Zhou X (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17:269-281.
29. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
30. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
31. Sathiapalan RK and El-Solh H (2001) Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18:543-546.
32. Schuhmacher J, Buhner K, and Witt-Laido A (2000) Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 89:1008-1021.
33. Sethi V, Jackson D, White D, Richards F, Stuart J, Muss H, Cooper M, and Spurr C (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41:3551-3555.
34. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, and Kim HS (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Can Med Assoc J 174:1715-1722.
35. Van den Berg H, Desai Z, Wilson R, Kennedy G, Bridges J, and Shanks R (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8:215-219.
36. Villikka K, Kivisto K, Maenpaa H, Joensuu H, and Neuvonen P (1999) Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 66:589-593.
37. Westland-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
38. Williams JA, Cook J, and Hurst SI (2003) A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 31:1526-1530.
39. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
40. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
41. Zhou-Pan X, Seree E, Zhou X, Placidi M, Maurel P, Barra Y, and Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53:5121-5126.